Tetraphase Pharmaceuticals Sees Unusually Large Options Volume (TTPH)

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 1,434 put options on the company. This represents an increase of approximately 2,461% compared to the average volume of 56 put options.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $5.23 on Friday. The company has a market cap of $268.90, a price-to-earnings ratio of -1.82 and a beta of 2.28. Tetraphase Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $9.93.

In other news, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares in the company, valued at $250,776. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $6.22, for a total transaction of $54,425.00. Following the sale, the insider now owns 8,750 shares in the company, valued at approximately $54,425. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in TTPH. Schwab Charles Investment Management Inc. lifted its holdings in Tetraphase Pharmaceuticals by 0.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after purchasing an additional 874 shares in the last quarter. Voya Investment Management LLC lifted its holdings in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 3,104 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Tetraphase Pharmaceuticals by 6.9% during the second quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 3,800 shares in the last quarter. California Public Employees Retirement System lifted its holdings in Tetraphase Pharmaceuticals by 2.0% during the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock valued at $1,727,000 after purchasing an additional 4,800 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Tetraphase Pharmaceuticals by 3.3% during the second quarter. Bank of New York Mellon Corp now owns 194,144 shares of the biopharmaceutical company’s stock valued at $1,384,000 after purchasing an additional 6,247 shares in the last quarter. Institutional investors own 58.36% of the company’s stock.

Several research firms recently commented on TTPH. BidaskClub lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 4th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, HC Wainwright raised their price target on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, November 6th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $15.15.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/09/tetraphase-pharmaceuticals-sees-unusually-large-options-volume-ttph.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply